6-[F-18]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma

Citation
K. Pacak et al., 6-[F-18]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma, HYPERTENSIO, 38(1), 2001, pp. 6-8
Citations number
17
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
HYPERTENSION
ISSN journal
0194-911X → ACNP
Volume
38
Issue
1
Year of publication
2001
Pages
6 - 8
Database
ISI
SICI code
0194-911X(200107)38:1<6:6PET(S>2.0.ZU;2-W
Abstract
The diagnosis and treatment of pheochromocytoma depend critically on effect ive means to localize the tumor. Computed tomography and magnetic resonance imaging have good sensitivity but poor specificity for detecting pheochrom ocytoma, and nuclear imaging approaches such as I-131-metaiodobenzylguanidi ne scintigraphy have limited sensitivity. Here we report initial results us ing 6-[F-18]fluorodopamine positron emission tomography (PET) scanning in t he diagnostic localization of pheochromocytoma. Twenty-eight patients with known or clinically suspected pheochromocytoma underwent PET scanning after intravenous injection of 6-[F-18]fluorodopamine. Of the 28 patients, 9 had surgical confirmation of the tumor, 8 had previously diagnosed metastatic pheochromocytoma, and I I had plasma levels of metanephrines that were with in normal limits. All 9 patients with surgically proven pheochromocytoma ha d abnormal 6-[F-18]fluorodopamine PET scans that identified the tumors. All 8 patients with metastatic pheochromocytoma had extra-adrenal sites of 6-[ F-18]fluorodopamine-derived activity. Of the I I patients with normal plasm a levels of metanephrines, 9 had negative 6-[F-18]fluorodopamine PET scans, I had extra-adrenal foci of 6-[F-18]fluorodopamine-derived activity, and I had symmetric uptake of 6-[F-18]fluorodopamine in the region of the adrena l glands. In patients with known disease, 6-[F-18]fluorodopamine PET scanni ng can detect and localize pheochromocytomas with high sensitivity. In pati ents in whom the diagnosis of pheochromocytoma is considered but excluded b ecause of negative plasma metanephrine results, 6-[F-18]fluorodopamine PET scans are consistently negative. These findings justify a clinical trial of 6-[F-18]fluorodopamine PET scanning as a diagnostic tool.